• Acorda Therapeutics Inc., of Hawthorne, N.Y., reported a GAAP net loss of $0.3 million for the second quarter, or 1 cent per share. Its non-GAAP income was $7.8 million, or 19 cents per share. Earnings for Ampyra (dalfampridine) for improved walking in patients with multiple sclerosis were $51.8 million over $28 million in the second quarter of 2010. Acorda earned $11.1 million from Zanaflex (tizanidine) for spasticity, and ended the quarter with $228.2 million in cash, cash equivalents and short-term investments. Acorda stock (NASDAQ:ACOR) fell $1.11, to close at $27.29 Monday.

• Auxilium Pharmaceuticals Inc., of Malvern, Pa., reported that its net loss for the second quarter was $5.1 million, or 11 cents per share, compared to a loss of $13.5 million, or 28 cents per share, for the second quarter of 2010. Revenues of $65.9 million were led by Testim (testosterone gel) for hypogonadism, which earned $50.5 million. Earnings for Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture, were $15.4 million. Auxilium ended the quarter with $151.8 million in cash, cash equivalents and short-term investments. Auxilium stock (NASDAQ:AUXL) fell $1.25, to close at $17.49 Monday.